Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Le Chesnay-Rocquencourt – page 21

3 344 clinical trials in Le Chesnay-Rocquencourt, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Le Chesnay-Rocquencourt at a glance
3 344
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 344 trials in Le Chesnay-Rocquencourt

Open in trial search

Hormone-dependent prostate cancer

Recruiting

Docetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard

Colorectal cancer metastatic

Recruiting

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Incyte Corp.

Non-small cell lung cancer

Recruiting

Zongertinib with cisplatin or carboplatin and pemetrexed, with or without pembrolizumab, for patients with locally advanced or metastatic non-squamous non-small cell lung cancer with HER2 mutations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Coagulation factor X level

Recruiting

VMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:VMX-C001
  • Sponsor:VarmX B.V.

Bladder cancer

Recruiting

Durvalumab and Chemotherapy in Adults With Muscle-Invasive Bladder Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Lymphogranuloma venereum

Recruiting

Doxycycline for Asymptomatic Anal LGV Infection in Patients with Asymptomatic Anal LGV Infection

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Doxycycline Monohydrate
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Systemic lupus erythematosus

Recruiting

Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Chronic myeloid leukaemia

Recruiting

Asciminib in Pediatric Patients With Philadelphia Positive Chronic Myeloid Leukemia in Chronic Phase

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Sponsor:Novartis Pharma AG

Neoplasm

Recruiting

Telisotuzumab Adizutecan for Locally Advanced or Metastatic Solid Tumors with MET Amplification in Patients 12 Years and Older

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Telisotuzumab adizutecan
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Neoplasm

Recruiting

EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:EIK1005 sodium
  • Sponsor:Eikon Therapeutics Inc.

Non-small cell lung cancer+1

Recruiting

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Acute promyelocytic leukaemia

Recruiting

QTX-2101 and Arsenic Trioxide in Adult Patients With Acute Promyelocytic Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Arsenic Trioxide
  • Sponsor:Quetzal Therapeutics LLC

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Le Chesnay-Rocquencourt

What the registry says about research in the country

01 Cardiology & Respiratory Medicine

Clinical trials focusing on acute myocardial infarction pain management and innovative treatments for severe asthma. Research includes evaluation of novel pain-relief methods and assessment of treatment discontinuation strategies.

  • Pain management in heart attacks
  • Asthma treatment optimization
  • Heart failure management

Studies also examine beta-blocker discontinuation in patients with recovered heart function.

02 Oncology & Hematology

Extensive research in blood cancers, including multiple myeloma, acute myeloid leukemia, and various lymphomas. Studies evaluate novel drug combinations and treatment strategies.

  • Blood cancer therapies
  • Leukemia treatments
  • Breast cancer management

Investigations include targeted therapies and personalized treatment approaches for various cancer types.

03 Pediatric & Infectious Diseases

Research focusing on respiratory syncytial virus (RSV) prevention in infants and children. Studies evaluate new protective treatments and their safety profiles.

  • RSV prevention
  • Infant protection studies
  • Immunotherapy research

Trials include assessment of novel medications for preventing severe respiratory infections in vulnerable populations.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.